Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Psoriasis Market Growth From $31.4 Billion In 2026 To $44.78 Billion By 2030 At A CAGR Of 9.3%
The psoriasis market size has shown significant growth in recent years. It is projected to increase from $28.93 billion in 2025 to $31.41 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.5%. The expansion witnessed historically can be attributed to several factors including the rising prevalence of autoimmune skin disorders, widespread usage of corticosteroids, improved diagnosis rates in dermatology, the expansion of hospital dermatology units, and increased awareness concerning chronic skin diseases.
The psoriasis market is anticipated to show significant growth in the coming years, with its size expected to reach $44.79 billion by 2030, reflecting a compound annual growth rate (CAGR) of 9.3%. This expansion during the forecast period is primarily driven by factors such as an increase in biologic drug approvals, heightened patient awareness, a rise in the diagnosis of severe psoriasis, the development of specialty clinics, and greater healthcare spending on dermatology. Noteworthy trends predicted for this period include the increased adoption of biologic therapies for psoriasis, the evolution of long-term disease management approaches, a growing demand for injectable psoriasis treatments, the broadening of hospital and specialty dermatology care, and an intensified focus on moderate-to-severe forms of the condition.
Get A Free Sample Report With In-Depth Market Insights:
Psoriasis Market Growth Factors: What’s Supporting Expansion?
The increasing number of individuals afflicted with psoriasis is anticipated to fuel the expansion of the psoriasis market in the coming years. Psoriasis is a persistent autoimmune skin condition marked by a rapid accumulation of skin cells, leading to inflammation, scaling, and discomfort, often necessitating continuous medical management and monitoring. This growth in psoriasis patients is attributed to an overactive immune system mistakenly attacking healthy skin cells, frequently triggered or exacerbated by environmental factors such as infections, stress, or skin trauma. The expanding presence of psoriasis supports the psoriasis market by generating greater demand for solutions like biologics, topical agents, immunomodulators, and phototherapy, all designed to lessen flare-ups, alleviate symptoms, and improve patient quality of life. For instance, in 2025, the Global Psoriasis Atlas, a UK-based research organization focused on psoriasis, estimated that 43 million people have psoriasis based on physician and dermatologist diagnoses, while approximately 102 million individuals reported having psoriasis based on self-reported cases. Therefore, the rising prevalence of psoriasis patients is a significant driver of the psoriasis market’s growth.
Psoriasis Market Segmentation: How Does The Market Break Down By Category?
The psoriasis market covered in this report is segmented –
1) By Drug class: Interleukin Inhibitors, Corticosteroids, Anti-Inflammatory, Tumor Necrosis Factor Inhibitor
2) By Drug Types: Small molecules, Biologics
3) By Disease Indication: Plaque Psoriasis, Nail Psoriasis, Guttate Psoriasis, Pustular Psoriasis, Erythrodermic Psoriasis
4) By Route Of Administration: Oral, Topical, Injectable
5) By Distribution Channel: Hospitals, Retail Pharmacies, E-Commerce
Subsegments:
1) By Interleukin Inhibitors: IL-12/23 Inhibitors (Ustekinumab), IL-17 Inhibitors (Secukinumab, Ixekizumab)
2) By Corticosteroids: Topical Corticosteroids (Hydrocortisone, Betamethasone), Systemic Corticosteroids (Prednisone)
3) By Anti-Inflammatory: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
4) By Tumor Necrosis Factor (TNF) Inhibitors: Adalimumab (Humira), Etanercept (Enbrel), Infliximab (Remicade)
Psoriasis Market Industry Trends: What’s Reshaping Demand?
Leading companies in the psoriasis market are concentrating on enhancing product innovation and formulations, such as developing autoinjector delivery systems for biosimilars. This focus aims to boost patient adherence, improve convenience, and optimize treatment outcomes, all while ensuring the efficacy and safety profiles remain consistent with reference biologics. These advancements allow for self-administration, alleviate injection-related discomfort, and encourage wider adoption of biosimilar therapies across Europe and other markets. For example, in May 2025, Sandoz, a biopharmaceutical company based in Switzerland, introduced the Pyzchiva autoinjector, marking it as the inaugural commercially available autoinjector for ustekinumab biosimilars in Europe. The Pyzchiva autoinjector is engineered to deliver biosimilar ustekinumab in a simple, accurate, and patient-friendly manner, thereby supporting improved adherence in the ongoing management of chronic psoriasis. This launch signifies a market shift towards improving patient-centric delivery methods for biologics and biosimilars, ultimately increasing accessibility and convenience for individuals living with psoriasis.
Psoriasis Market Competitive Overview And Top Companies
Major companies operating in the psoriasis market are AbbVie Inc., Pfizer Inc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, Amgen Inc., Merck & Co. Inc., Janssen Biotech Inc., Takeda Pharmaceutical Company Limited, Union Chimique Belge SA, Sun Pharmaceutical Industries Ltd., Almirall SA, Bausch Health Companies Inc., Biogen Inc., Biocon Biopharmaceuticals Pvt. Ltd., Celltrion Inc., Dr.Reddy’s Laboratories Inc., Arcutis Biotherapeutics Inc., Bayer AG, Bristol Myers Squibb Co., Galderma SA, GlaxoSmithKline Plc, Incyte Pharmaceuticals Corp., LEO Pharmacy
View The Full Psoriasis Market Report:
Psoriasis Market Leading Geography: Which Region Contributes The Most Revenue?
North America was the largest region in the psoriasis market in 2025. Middle East is expected to be the fastest-growing region in the psoriasis market during the forecast period. The regions covered in the psoriasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
